Hodgkin Lymphoma News and Research

RSS

Cancer risks for overweight women

Half of all cases of womb cancer and a type of oesophageal cancer in women are caused by being overweight or obese, according to a new report published online in the British Medical Journal.

6 Nov 2007

Vitamin D protects against colorectal cancer

According to a new study by researchers at the U.S. National Cancer Institute (NCI) there is no link between vitamin D levels and the overall risk of dying from cancer.

31 Oct 2007

Quantitative PET imaging finds early determination of effectiveness of cancer treatment

With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient's response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors.

24 Oct 2007

Re-engineered human T cells effectively target and kill cancerous B cells

Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).

18 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Pharmion and MethylGene announce orphan drug designation for treatment of Hodgkin's lymphoma

Pharmion Corporation, along with its collaborator MethylGene Inc., today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States.

21 Aug 2007

Genta and Emisphere Technologies file investigational new drug exemption

Genta Inc. and Emisphere Technologies, Inc. have jointly announced the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S. Food and Drug Administration (FDA) for a new drug known as G4544.

2 Aug 2007

New target for Hodgkin lymphoma

Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells.

1 Aug 2007

Study looks at cancer incidence among recipients of blood from donors

Individuals who receive blood transfusions from donors with undiagnosed cancers are at no higher risk of developing malignant disease than people who receive blood from donors without cancer, according to the results of a retrospective study published in The Lancet last month.

23 Jul 2007

Blood transfusions not likely to spread cancer

23 Jul 2007

Prevention and treatment of vitamin D deficiency

Boston, MA:In a review article to appear in the July 19th issue of the New England Journal of Medicine, Dr. Michael Holick, an internationally recognized expert in vitamin D, provides an overview of his pioneering work that expounds on the important role vitamin D plays in a wide variety of chronic health conditions, as well as suggesting strategies for the prevention and treatment of vitamin D deficiency.

19 Jul 2007

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

Cancer risk in HIV, transplant patients

HIV/AIDS and kidney transplant patients are at much greater risk of contracting 20 different types of cancer than the general population, according to a land mark paper in The Lancet.

8 Jul 2007

New type of drug shows promise for chronic lymphocytic leukemia

A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

29 Jun 2007

Biovest announces interim blinded data of fast-tracked pivotal phase 3 clinical trial of BiovaxID

Biovest International announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006.

29 Jun 2007

Study finds lymphoma drug effective over long term

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.

5 Jun 2007

Adding radioimmunotherapy to chemo may help patients with lymphoma

Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.

5 Jun 2007

Heart-assist device gives Culver City man a better quality of life

Mark Heiner of Culver City reads books, paints artistically, takes walks and does laundry – activities that would be considered routine except for the fact that a four-pound disk implanted in his abdominal cavity is keeping his blood flowing.

28 May 2007

Some cancers linked to extremely low frequency electromagnetic fields

The researchers opted to study this group, because railway workers in Switzerland tend to change jobs infrequently and are exposed to much higher levels of electromagnetic field radiation than the general population.

24 May 2007